NCT05888597Not yet recruiting
Efficacy of L-menthol on Breathlessness in Chronic Obstructive Pulmonary Disease
Effect of L-menthol on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease: a Randomized
Region SkanePhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Chronic Obstructive Pulmonary Disease (COPD)
- Drug/Device/Intervention
- L-menthol
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Region Skane
- Location
- Lund, Sweden
Timeline & enrollment
- Phase
- Phase 2
- Start date
- May 24, 2023
- End date
- Dec 30, 2024
- Enrollment
- 20 participants
Primary outcome
Breathlessness intensity
Summary
The purpose of this study is to assess the effect of L-menthol on breathlessness in patients
 with chronic obstructive pulmonary disease (COPD).
ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05888597
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05888597 through Pure Global AI's free database. This Phase 2 trial is sponsored by Region Skane and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.